5,015 Shares in Myokardia Inc (MYOK) Purchased by Amalgamated Bank

Amalgamated Bank purchased a new position in shares of Myokardia Inc (NASDAQ:MYOK) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 5,015 shares of the biotechnology company’s stock, valued at approximately $245,000.

A number of other hedge funds have also recently bought and sold shares of MYOK. Hillhouse Capital Advisors Ltd. acquired a new position in Myokardia during the 4th quarter worth approximately $41,938,000. Vanguard Group Inc raised its stake in shares of Myokardia by 32.8% in the third quarter. Vanguard Group Inc now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after purchasing an additional 740,607 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Myokardia by 32.8% in the third quarter. Vanguard Group Inc. now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after purchasing an additional 740,607 shares during the last quarter. BB Biotech AG raised its stake in shares of Myokardia by 72.0% in the fourth quarter. BB Biotech AG now owns 877,266 shares of the biotechnology company’s stock worth $42,863,000 after purchasing an additional 367,266 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in shares of Myokardia in the fourth quarter worth approximately $16,373,000. 90.88% of the stock is currently owned by institutional investors and hedge funds.

Shares of Myokardia stock opened at $50.02 on Tuesday. The company has a market capitalization of $2.05 billion, a PE ratio of -28.42 and a beta of 2.48. Myokardia Inc has a 52 week low of $39.01 and a 52 week high of $67.79.



Myokardia (NASDAQ:MYOK) last issued its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.07. The company had revenue of $12.40 million during the quarter, compared to the consensus estimate of $8.57 million. Myokardia had a negative return on equity of 20.00% and a negative net margin of 201.81%. As a group, equities research analysts predict that Myokardia Inc will post -3.16 EPS for the current year.

Several analysts have recently commented on MYOK shares. BidaskClub downgraded Myokardia from a “hold” rating to a “sell” rating in a research note on Saturday, February 9th. ValuEngine downgraded Myokardia from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 15th. BMO Capital Markets started coverage on Myokardia in a research note on Friday, February 22nd. They issued an “outperform” rating and a $85.00 price objective for the company. TheStreet raised Myokardia from a “d+” rating to a “c-” rating in a research note on Thursday, April 4th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $90.00 price objective on shares of Myokardia in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $75.80.

In related news, major shareholder Sanofi sold 4,168,899 shares of the stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $37.66, for a total transaction of $157,000,736.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Taylor C. Harris sold 1,324 shares of the stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $53.30, for a total value of $70,569.20. Following the sale, the chief financial officer now directly owns 3,750 shares of the company’s stock, valued at $199,875. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.

WARNING: This piece of content was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/04/16/5015-shares-in-myokardia-inc-myok-purchased-by-amalgamated-bank.html.

About Myokardia

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

Featured Article: What is the balance sheet?

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).

Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.